For research use only. Not for therapeutic Use.
Homoharringtonine (Cat.No:I002922) is a natural alkaloid derived from the Cephalotaxus genus of evergreen trees. It exhibits potent antitumor activity by inhibiting protein synthesis in cancer cells. Homoharringtonine is primarily used in the treatment of certain types of leukemia, such as chronic myeloid leukemia, and has shown promising results in clinical trials for other malignancies as well.
| Catalog Number | I002922 |
| CAS Number | 26833-87-4 |
| Synonyms | CGX-635;HHT;NSC 141633;Omacetaxine Mepesuccinate |
| Molecular Formula | C29H39NO9 |
| Purity | ≥95% |
| Target | Others |
| Solubility | 10 mM in DMSO |
| Storage | 2°C to 8°C |
| InChIKey | HYFHYPWGAURHIV-JFIAXGOJSA-N |
| Reference | </br>1:Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts. Chen P, Yuan Q, Yang H, Wen X, You P, Hou D, Xie J, Cheng Y, Huang H.Leuk Res. 2017 Apr 25;57:119-126. doi: 10.1016/j.leukres.2017.04.007. [Epub ahead of print] PMID: 28463768 </br>2:Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells. Chen J, Mu Q, Li X, Yin X, Yu M, Jin J, Li C, Zhou Y, Zhou J, Suo S, Lu D, Jin J.Oncotarget. 2017 Apr 8. doi: 10.18632/oncotarget.16956. [Epub ahead of print] PMID: 28454099 Free Article</br>3:[Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review]. Wang Q, Li YF.Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Apr;25(2):596-599. doi: 10.7534/j.issn.1009-2137.2017.02.052. Chinese. PMID: 28446318 </br>4:[Effect of Autophagy on Homoharringtonine-treated K562 Cells]. Lu XY, Ye LL, Shi YY, Ding YH, Li YF.Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Apr;25(2):412-417. doi: 10.7534/j.issn.1009-2137.2017.02.019. Chinese. PMID: 28446285 </br>5:Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines. Wang Q, Ding W, Ding Y, Ma J, Qian Z, Shao J, Li Y.Oncotarget. 2017 Mar 31. doi: 10.18632/oncotarget.16731. [Epub ahead of print] PMID: 28410239 Free Article</br>6:Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china. Liu H, Zhang J, Ren S, Chen M, Liu L, Zhang H.Leuk Lymphoma. 2017 Apr 13:1-4. doi: 10.1080/10428194.2017.1312378. [Epub ahead of print] No abstract available. PMID: 28406352 </br>7:Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Maiti A, Cortes J, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O/’Brien S, Kantarjian H.Leuk Lymphoma. 2017 Feb 9:1-6. doi: 10.1080/10428194.2017.1283030. [Epub ahead of print] No abstract available. PMID: 28278723 </br>8:[Effect of Homoharringtonine Combined with Imatinib on the K562/G01 Cells and Its Mechanism]. Wu JJ, Ding YH, Deng ZK, Shi YY, Lu XY, Li YF.Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Feb;25(1):80-84. doi: 10.7534/j.issn.1009-2137.2017.01.013. Chinese. PMID: 28245379 </br>9:The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia. Li X, Yin X, Wang H, Huang J, Yu M, Ma Z, Li C, Zhou Y, Yan X, Huang S, Jin J.Oncotarget. 2017 Feb 21;8(8):12764-12774. doi: 10.18632/oncotarget.14463. PMID: 28061447 Free PMC Article</br>10:PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells. Li M, Shi F, Fei X, Wu S, Wu D, Pan M, Luo S, Gu N, Dou J.Exp Biol Med (Maywood). 2017 May;242(9):996-1004. doi: 10.1177/1535370216685008. Epub 2017 Jan 1. PMID: 28056549 |
